Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 6/20 | 0.63 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.56 |
| ▸ | CPT1A | P50416 | 1/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7151503 | 0.85 | PTGER4 (0.60) | PTGER4FSCN1CPT1APTGDR2HIF1A | |
| SCHEMBL28654838 | 0.84 | PTGER4 (0.72) | PTGER4FSCN1CPT1ACNR1 | |
| SCHEMBL3428761 | 0.84 | PTGER4 (0.61) | PTGER4FSCN1CPT1APTGDR2HIF1A | |
| SCHEMBL3430198 | 0.84 | KDM4E (0.51) | PTGER4CNR1 | |
| SCHEMBL3430287 | 0.82 | PTGER4 (0.57) | PTGER4FSCN1CPT1A | |
| SCHEMBL3428602 | 0.82 | PTGER4 (0.63) | PTGER4FSCN1CNR1SMN1; SMN2 | |
| SCHEMBL24273438 | 0.80 | PTGER4 (0.72) | PTGER4CNR1 | |
| SCHEMBL25347539 | 0.80 | PTGER4 (0.72) | PTGER4FSCN1CPT1AHIF1ACNR1 | |
| SCHEMBL3430292 | 0.80 | PTGER4 (0.61) | PTGER4PTGDR2HIF1ACNR1SMN1; SMN2 | |
| SCHEMBL17038816 | 0.80 | PTGER4 (0.65) | PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | claimed |
| EP-2257340-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-12-08 | — | — | EP | disclosed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED | 2010-12-02 | — | — | US | disclosed |
| WO-2009121623-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009121623-A2 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305120-A1 | COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY | CPT1B, SMN1; SMN2, GYS1 | PTGER4 3500/4885FSCN1 2107/4885CPT1A 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.